omeprazole has been researched along with Abnormalities, Drug-Induced in 8 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications." | 9.08 | The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998) |
| "To evaluate the magnitude of possible fetal risks involved in maternal use of omeprazole during pregnancy." | 7.71 | Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy. ( Källén, BA, 2001) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| "Our purpose was to determine whether omeprazole use during pregnancy is associated with an increased risk of malformations, spontaneous abortions, decreased birth weight, or perinatal complications." | 5.08 | The safety of omeprazole during pregnancy: a multicenter prospective controlled study. ( Addis, A; Bonati, M; Koren, G; Lalkin, A; Loebstein, R; Mastroiacovo, P; Mazzone, T; Ramezani-Namin, F; Vial, T, 1998) |
| "To evaluate the magnitude of possible fetal risks involved in maternal use of omeprazole during pregnancy." | 3.71 | Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy. ( Källén, BA, 2001) |
| "Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy." | 2.41 | Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. ( Abdollahi, M; Koren, G; Magee, LA; Moretti, ME; Nikfar, S, 2002) |
| " Rates of congenital malformations in PPIs exposed and unexposed pregnancies, as well as other adverse fetal effects were compared." | 1.38 | The safety of fetal exposure to proton-pump inhibitors during pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Uziel, E; Wiznitzer, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matok, I | 1 |
| Levy, A | 1 |
| Wiznitzer, A | 1 |
| Uziel, E | 1 |
| Koren, G | 4 |
| Gorodischer, R | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Moretti, ME | 1 |
| Magee, LA | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Lalkin, A | 2 |
| Magee, L | 1 |
| Addis, A | 2 |
| Loebstein, R | 2 |
| Källén, B | 1 |
| Ramezani-Namin, F | 1 |
| Mastroiacovo, P | 1 |
| Mazzone, T | 1 |
| Vial, T | 1 |
| Bonati, M | 1 |
| Ruigómez, A | 1 |
| García Rodríguez, LA | 1 |
| Cattaruzzi, C | 1 |
| Troncon, MG | 1 |
| Agostinis, L | 1 |
| Wallander, MA | 1 |
| Johansson, S | 1 |
| Källén, BA | 1 |
1 review available for omeprazole and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Female; Fetus; Gastroesophageal Reflux; Humans; Maternal-Fetal Exchange | 2002 |
2 trials available for omeprazole and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
The safety of omeprazole during pregnancy: a multicenter prospective controlled study.
Topics: Abnormalities, Drug-Induced; Adult; Birth Weight; Delivery, Obstetric; Enzyme Inhibitors; Female; Ga | 1998 |
5 other studies available for omeprazole and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Cohort Studies; Databas | 2012 |
Acid-suppressing drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Ulcer Agents; Cohort Studies; Female; Fetus; Gastroesophageal Refl | 1997 |
Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anti-Ulcer Agents; Cohort Studies; Female; Histamine | 1998 |
Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Anti-Ulcer Agents; Cimetidine; Cohort Studies; Female; Humans; Infant, | 1999 |
Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anti-Ulcer Agents; Apgar Score; Birth W | 2001 |